香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股份代號：2629） Mirxes Holding Company Limited Mirxes Holding Company Limited 執行董事兼首席執行官 周礪寒博士 董事會召開日期 Mirxes Holding Company Limited（「本公司」）董事（「董事」）會（「董事會」）謹此宣 佈，謹定於2026年3月31日（星期二）舉行董事會會議，藉以（其中包括）考慮及 通過本公司及其附屬公司截至2025年12月31日止的年度全年綜合業績以供發佈， 並考慮建議派發末期股息（如有），以及處理任何其他事項。 承董事會命 香港，2026年3月19日 於本公告日期，董事會包括(i)執行董事周礪寒博士及鄒瑞陽博士；(ii)非執行董事朱興奮博士、 樂貝林博士及柳達先生；及(iii)獨立非執行董事林倩麗博士、方曉先生及馬露玲女士。 ...

Mirxes Holding Company Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股份代號：2629） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 自願性公告 中標2026年濂溪區胃癌篩查和早期干預項目 本公告乃由Mirxes Holding Company Limited（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，旨在知會本公司股東及潛在投資者有關本集團的最新業務 發展。 2026年濂溪區胃癌篩查和早期干預項目 本公司董事（「董事」）會（「董事會」）宣佈，於2026年3月3日，本公司成功中標 2026年濂溪區胃癌篩查和早期干預項目（「該項目」），這是本公司首個公共衛生 癌症早篩項目，也是其在中國首個政府採購項目，標誌著其miRNA液體活檢技 術正式進入公共衛生體系，為胃癌早篩規模化落地奠定關鍵基礎。 該項目預算金額人民幣810.0萬元，最高投標價人民幣769.5萬元，將為中國江 西九 ...

Group 1: Pharmaceutical and Biotechnology Sector - Four Seasons Pharmaceutical (00460) saw a stock increase of 3.7% after receiving approval from the NMPA for its innovative drug, Pyrocilin Tablets, for treating HR+/HER2- advanced breast cancer [1] - Hengrui Medicine (01276) rose over 5% following the approval of a clinical trial for HRS-1780 Tablets aimed at treating primary hyperaldosteronism [3] - Mirxes-B (02629) experienced a stock surge of 10.86% after announcing a strategic partnership with Apollo Health to develop advanced cancer early detection solutions in India [3] - Cornerstone Pharmaceuticals-B (02616) increased by 12.37% after receiving FDA approval for its IND application for CS2009, a tri-specific antibody for advanced solid tumors [4] - Deciphera Pharmaceuticals-B (06996) rose 16.77% after signing an agreement with U.S. Biotech for the global development and commercialization of ATG-201, a dual-specific T-cell engager [5] Group 2: Automotive Sector - Automotive stocks showed a collective rebound, with XPeng Motors-W (09868) up 3.14% and NIO-SW (09866) up 3.43%, driven by news of BYD's upcoming launch of its second-generation blade battery and fast-charging technology [2] Group 3: Technology and Communication Sector - Optical communication stocks rallied, with Cambridge Technology (06166) up 8.7% after NVIDIA announced a $40 billion investment in optical technology through partnerships with Lumentum and Coherent [1] - Brain-computer interface stocks surged, with Nanjing Panda Electronics (00553) increasing by 24.64% following government reports emphasizing the development of future industries, including brain-computer interfaces [2] Group 4: Cryptocurrency Sector - Cryptocurrency-related stocks rebounded, with Okex Cloud Chain (01499) rising 15.89% as Bitcoin surpassed $72,000, driven by short-covering amid geopolitical concerns [5][6]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02629 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.00001 USD | | | 100,000 | | 增加 / 減少 (-) | | | | | | USD | | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.00001 USD | | | 100,000 | 本月底法定/註冊股本總額： USD 100,000 第 1 頁 共 1 ...

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies [1][2]. Group 1: Companies with Increased Holdings - Southern Hong Kong American Technology (03442) saw the largest increase in holdings, up by 6.37% to a total holding of 37.93% [2]. - Shandong Molong (00568) experienced a 3.20% increase, bringing its holding to 56.76% [2]. - MIRXES HOLDING COMPANY LIMITED (02629) had a 2.16% increase, resulting in a holding of 7.15% [2]. - Over the last five trading days, Southern East Selection (03441) had the highest increase at 18.72%, with a new holding of 41.29% [3]. - The total increase in holdings for the top three companies over the last five days was 6.91% for Southern Hong Kong American Technology (03442) [3]. Group 2: Companies with Decreased Holdings - Lion Group Holdings (02562) had the largest decrease in holdings, down by 0.49% to 51.00% [2]. - Zhejiang Shibao (01057) saw a decrease of 0.47%, resulting in a holding of 55.85% [2]. - Ganfeng Lithium (01772) experienced a 0.45% decrease, bringing its holding to 33.59% [2]. - In the last five trading days, Beijing Capital International Airport (00694) had the largest decrease at 0.95%, with a holding of 26.29% [3]. - The total decrease in holdings for the top three companies over the last five days was 0.79% for Jiangxi Copper (00358) [3].

Core Viewpoint - Mirxes has signed a memorandum of understanding with Apollo Health and Lifestyle to jointly develop and commercialize advanced cancer early screening solutions in India and surrounding countries, planning to establish a joint venture valued at no less than $50 million [1][6]. Group 1: Market Opportunity and Strategic Moves - The global tumor early screening market is projected to grow at a compound annual growth rate (CAGR) of 19.2% from 2024 to 2028, making this strategic partnership a crucial step for Mirxes to enhance its competitiveness and break regional limitations [1]. - Mirxes recently completed the enrollment of 6,000 participants in the largest colorectal cancer blood early screening clinical trial in Southeast Asia, marking a significant milestone for the company [2]. - The company raised approximately HKD 700 million in February, with 20% allocated for expanding into emerging markets like India, creating a strong foundation for its market penetration efforts [2][6]. Group 2: Technological and Product Development - The collaboration with Apollo opens up the rapidly growing healthcare market in India, where cancer incidence is high, with a lifetime risk of 11% for cancer [3]. - Mirxes' colorectal cancer early screening product has shown over 80% sensitivity and about 90% specificity, tailored for the Asian population, significantly enhancing its market adaptability [3][7]. - The product pipeline includes a gastric cancer early screening product, which is the first approved IVD product for gastric cancer, expected to generate stable cash flow starting in 2025 [4]. Group 3: Competitive Advantage and Market Positioning - Mirxes has established a strong technical barrier and a rich product pipeline, with its core technology in miRNA being a key differentiator in the liquid biopsy field [7]. - The partnership with Apollo allows Mirxes to leverage Apollo's extensive healthcare network to accelerate commercialization and optimize product parameters for the Indian population [8]. - The collaboration is expected to extend into preventive medicine, broadening Mirxes' business scope beyond cancer screening [8]. Group 4: Response to Public Health Needs - The partnership coincides with public health challenges in India, such as the Nipah virus outbreak, highlighting the urgent need for rapid and convenient home testing solutions [11]. - Mirxes' technology platform can be adapted for infectious disease rapid testing, addressing public health emergencies while also entering the consumer health testing market [11]. Group 5: Financial and Market Dynamics - The establishment of the joint venture is not merely conceptual but involves real funding, technology licensing, and synchronized commercialization efforts, providing a clear valuation anchor for Mirxes' Indian operations [12]. - The current stock price reflects previous liquidity pressures and conservative market expectations, with the partnership expected to drive value release through commercialization and globalization [12].

本次合作将Mirxes的突破性miRNA及多组学技术、核心产品(GASTROClear及 LUNGClear)及其日益成 熟的临床管线(涵盖结直肠癌、肝癌、乳癌的成熟临床管线及CADENCE多癌种检测)与Apollo丰富的临 床专业知识、全国医院网络及社区医疗服务的提供能力结合，以实现宏伟的愿景：及早检测癌症、于可 治愈时介入及改变数百万患者的治疗结果。 智通财经APP讯，MIRXES-B(02629)发布公告，本公司已与Apollo Health and Lifestyle Limited(AHLL， 为 Apollo Hospitals Enterprise Limited(Apollo)的全资附属公司)订立谅解备忘录以寻求进行战略合作，从 而于印度及邻近国家共同开发及商业化先进的癌症早期检测解决方案。待达成协定目标及获各自董事会 批准后，预期将会于印度创立一家合营公司，根据本公司及Apollo 将注入的知识产权、临床管线、研 发、临床试验基础设施及商业渠道，其股权价值将不少于5000万美元。 作为亚洲首屈一指的医疗服务提供者，Apollo及AHLL于南亚及中东以其先进医疗服务而广受认可，并 致力于提升其 ...

Group 1 - MIRXES-B has signed a memorandum of understanding with Apollo Health and Lifestyle Limited to seek strategic cooperation for the development and commercialization of advanced cancer early detection solutions in India and neighboring countries [1] - The anticipated joint venture in India will have a minimum equity value of $50 million, based on the intellectual property, clinical pipeline, research and clinical trial facilities, and commercial channels contributed by both companies [1] - Apollo is recognized as a leading healthcare provider in Asia and aims to enhance its global leadership position in preventive oncology and disease management [1] Group 2 - The collaboration will combine Mirxes' breakthrough miRNA and multi-omics technologies, core products (GASTROClear and LUNGClear), and its mature clinical pipeline with Apollo's extensive clinical expertise and nationwide hospital network [2] - The goal of the partnership is to scale the commercialization and market adoption of these solutions, thereby expanding the coverage of early disease screening in the region [2] - The board believes that this strategic cooperation with Apollo represents a significant synergistic opportunity that aligns with the long-term strategic goals of the company [2]

本公告乃由Mirxes Holding Company Limited（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，旨在知會本公司股東及潛在投資者有關本集團的最新業務 發展。 諒解備忘錄 本公司董事（「董事」）會（「董事會」）宣佈，本公司已與Apollo Health and Lifestyle Limited（「AHLL」，為Apollo Hospitals Enterprise Limited（「Apollo」）的全資附屬公 司）訂立諒解備忘錄（「諒解備忘錄」）以尋求進行戰略合作，從而於印度及鄰近 國家共同開發及商業化先進的癌症早期檢測解決方案。待達成協定目標及獲 各自董事會批准後，預期將會於印度創立一家合營公司，根據本公司及Apollo 將注入的知識產權、臨床管線、研發、臨床試驗基礎設施及商業渠道，其股權 價值將不少於50百萬美元。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 Mirxes Holding Company Limite ...

Company News - Tongguan Gold (00340.HK) expects a net profit of approximately HKD 820 million to HKD 840 million in 2025, representing a year-on-year increase of about 289% to 298%, mainly due to increased production and sales of gold and higher average selling prices [1] - China State Construction Industry (00830.HK) anticipates a net profit of approximately HKD 237 million for the fiscal year 2025, down from HKD 650 million in the previous year, primarily due to a decrease in new project volume and revenue [1] - Kintor Group (00148.HK) projects a net profit growth of over 165% in 2025, exceeding HKD 4.32 billion, driven by growth in investment business and profits from copper-clad laminates [1] - Kintor Laminates (01888.HK) expects a net profit increase of over 80% in 2025, exceeding HKD 2.39 billion, attributed to strong demand for copper-clad laminates and upstream materials including fiberglass yarn, fiberglass cloth, and copper foil [1] - China Starch (03838.HK) forecasts total revenue of RMB 10.058 billion in 2025, with a pre-tax profit of RMB 838 million, a significant decrease of approximately 64% year-on-year [2] Other Developments - Wuyi Vision (06651.HK) has successfully completed systematic adaptation and deep optimization of SimOne 4.0 on the Moore Thread MTT S5000 GPU [3] - China Resources Land (03377.HK) issued a total of 1,996,400 new shares due to the conversion of mandatory convertible bonds [3] - Cornerstone Pharmaceuticals-B (02616.HK) received approval from the UK MHRA for a new indication of Sugliucan in the treatment of small cell lung cancer [4] - MIRXES-B (02629.HK) completed the enrollment process for the CADENCE CRC study [5] - Jingrui Holdings (01862.HK) received additional resumption guidance from the Stock Exchange and continues to be suspended [6] Buyback Activities - Xuanwu Cloud (02392.HK) repurchased 4,000 shares at a cost of HKD 6.22778 million, with buyback prices ranging from HKD 1.52 to HKD 1.57 [7] - Geely Automobile (00175.HK) spent HKD 11.263 million to repurchase 659,000 shares, with buyback prices between HKD 16.99 and HKD 17.18 [8] - NetEase Cloud Music (09899.HK) repurchased approximately HKD 14.9977 million worth of 94,500 shares, with buyback prices ranging from HKD 157.2 to HKD 160.9 [9]